Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus NephritisPRNewsWire • 10/17/23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus NephritisGlobeNewsWire • 10/17/23
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost MeasuresGlobeNewsWire • 10/16/23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 08/10/23
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 WeeksZacks Investment Research • 06/28/23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid LeukemiaGlobeNewsWire • 06/27/23
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy ProgramGlobeNewsWire • 06/26/23
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant LymphomaGlobeNewsWire • 06/10/23
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant LymphomaGlobeNewsWire • 05/11/23
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual MeetingGlobeNewsWire • 04/17/23
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 03/16/23